Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 5
1985 2
1986 5
1987 11
1988 9
1989 9
1990 8
1991 17
1992 22
1993 15
1994 24
1995 22
1996 23
1997 31
1998 21
1999 23
2000 42
2001 21
2002 36
2003 49
2004 45
2005 55
2006 45
2007 51
2008 48
2009 59
2010 50
2011 77
2012 62
2013 82
2014 68
2015 70
2016 92
2017 76
2018 70
2019 79
2020 60
2021 76
2022 85
2023 78
2024 79
2025 62
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,748 results

Results by year

Filters applied: . Clear all
Page 1
Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single-center experience.
Feng D, Huang Z, Chen H, Tao J, Gao X, Liu J, Sun L, Wang Z, Han Z, Ju X, Tan R, Gu M. Feng D, et al. Clin Transplant. 2022 Apr;36(4):e14565. doi: 10.1111/ctr.14565. Epub 2022 Jan 11. Clin Transplant. 2022. PMID: 34931720
OBJECTIVE: To evaluate the clinical efficacy and safety of iguratimod (IGU) for reducing panel reactive antibody (PRA) in high-mismatched renal transplant recipients. METHODS: Eligible recipients positive for PRAs who received or did not receive IGU treatment …
OBJECTIVE: To evaluate the clinical efficacy and safety of iguratimod (IGU) for reducing panel reactive antibody (PRA) …
Association between calculated panel reactive antibody and waitlist outcomes in the 2018 heart allocation system.
DeFilippis EM, Ji Z, Masotti M, Maharaj V, Alexy T, Kittleson MM, Cogswell R. DeFilippis EM, et al. J Heart Lung Transplant. 2023 Oct;42(10):1469-1477. doi: 10.1016/j.healun.2023.05.018. Epub 2023 Jun 1. J Heart Lung Transplant. 2023. PMID: 37268050
METHODS: Adult waitlist outcomes in OPTN (October 2018-September 2022) by calculated panel reactive antibody (cPRA) were modeled to identify thresholds of clinical significance. ...
METHODS: Adult waitlist outcomes in OPTN (October 2018-September 2022) by calculated panel reactive antibody (cPRA) wer …
A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody 99.9.
Cucchiari D, Mancebo-Sierra E, Caro JL, Meneghini M, Pérez-Saez MJ, López BR, Redondo-Pachón D, Arana C, Bestard O, Andrés A, Moreso F, Crespo M, Palou E, Diekmann F. Cucchiari D, et al. Kidney Int. 2025 Nov;108(5):927-937. doi: 10.1016/j.kint.2025.04.031. Epub 2025 Jun 6. Kidney Int. 2025. PMID: 40484353
INTRODUCTION: In kidney transplant candidates with calculated Panel Reactive Antibody (cPRA) 99.9%, looking for perfect HLA compatibility may delay transplantation beyond a reasonable waiting time. However, the presence of preformed donor-specific antibody …
INTRODUCTION: In kidney transplant candidates with calculated Panel Reactive Antibody (cPRA) 99.9%, looking for perfect …
Pretransplant Calculated Panel Reactive Antibody in the Absence of Donor-Specific Antibody and Kidney Allograft Survival.
Lan JH, Kadatz M, Chang DT, Gill J, Gebel HM, Gill JS. Lan JH, et al. Clin J Am Soc Nephrol. 2021 Feb 8;16(2):275-283. doi: 10.2215/CJN.13640820. Epub 2021 Jan 25. Clin J Am Soc Nephrol. 2021. PMID: 33495290 Free PMC article.
BACKGROUND AND OBJECTIVES: Panel reactive antibody informs the likelihood of finding an HLA-compatible donor for transplant candidates, but has historically been associated with acute rejection and allograft survival because testing methods could not exclude …
BACKGROUND AND OBJECTIVES: Panel reactive antibody informs the likelihood of finding an HLA-compatible donor for transp …
The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation.
Chang D, Kobashigawa J. Chang D, et al. Curr Opin Organ Transplant. 2012 Aug;17(4):423-6. doi: 10.1097/MOT.0b013e328355f195. Curr Opin Organ Transplant. 2012. PMID: 22790077 Review.
PURPOSE OF REVIEW: Alloantibodies to human leukocyte antigens (HLAs) in patients awaiting heart transplantation are associated with prolonged wait time to transplant, increased risk of posttransplant rejection and cardiac allograft vasculopathy, and decreased survival. Solid-phas …
PURPOSE OF REVIEW: Alloantibodies to human leukocyte antigens (HLAs) in patients awaiting heart transplantation are associated with prolonge …
Pediatric cardiac transplantation in children with high panel reactive antibody.
Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V, van Gelder HM, Asante-Korang A, McCormack J, Daicoff GR. Jacobs JP, et al. Ann Thorac Surg. 2004 Nov;78(5):1703-9. doi: 10.1016/j.athoracsur.2004.03.031. Ann Thorac Surg. 2004. PMID: 15511459 Review.
BACKGROUND: Elevated panel reactive antibody (PRA) may be considered a risk factor precluding pediatric orthotopic heart transplantation. ...
BACKGROUND: Elevated panel reactive antibody (PRA) may be considered a risk factor precluding pediatric orthotopic hear …
Spanish guidelines for kidney transplantation in highly sensitized patients with donor-specific anti-HLA antibodies.
Mancebo E, Diekmann F, Palou E, Vilches C, Crespo M, Mazuecos A, Caro JL, Cruzado JM, Segundo DS, Muro M, Ontañón J, Álvarez A, Bestard O, Fernández C, González MF, Nieto A, Vega R, Paz-Artal E, Coll E, Andrés A, Domínguez-Gil B. Mancebo E, et al. Transplant Rev (Orlando). 2025 Jul;39(3):100919. doi: 10.1016/j.trre.2025.100919. Epub 2025 Apr 3. Transplant Rev (Orlando). 2025. PMID: 40209457 Review.
Highly sensitized patients awaiting kidney transplantation face substantial challenges due to the presence of potential donor-specific anti-HLA antibodies (DSA). These antibodies increase the risk of antibody-mediated rejection (ABMR), but also complicate the …
Highly sensitized patients awaiting kidney transplantation face substantial challenges due to the presence of potential donor-specific anti- …
The correlation of results of panel reactive antibody, identification, and single antigen beads in detection of anti-HLA antibodies: Istanbul Faculty of Medicine, tissue typing laboratory experience.
Ciftci HS, Oguz FS, Cinar CK, Izgi DK. Ciftci HS, et al. Transpl Immunol. 2023 Oct;80:101891. doi: 10.1016/j.trim.2023.101891. Epub 2023 Jul 9. Transpl Immunol. 2023. PMID: 37433395
BACKGROUND: We have performed a retrospective analysis of anti-HLA class I MHC and class II MHC antibodies measured using a single antigen bead (SAB) assay and a panel reactive antibody (PRA) assay. ...Antibodies against both class I/II antigens …
BACKGROUND: We have performed a retrospective analysis of anti-HLA class I MHC and class II MHC antibodies measured using a single an …
Development of a calculated panel reactive antibody calculator for the United Arab Emirates: a proof of concept study.
Alvares M, Anwar S, Hashmi SK, Zaman MB, Al Mahri A, Alvares C, Al Katheeri L, Purushothaman A, Ralonya ME, Sangalang MG, Jannang R, Abdulle A, Al Qubaisi A, Al Ahmed M, Khamis AH, Al Seiari M, Al Obaidli A, Al Yafei Z, ElGhazali G. Alvares M, et al. Sci Rep. 2023 May 25;13(1):8468. doi: 10.1038/s41598-023-34860-y. Sci Rep. 2023. PMID: 37231090 Free PMC article.
Calculated panel reactive antibody (CPRA) is used to help increase sensitized patient's access to transplantation. ...
Calculated panel reactive antibody (CPRA) is used to help increase sensitized patient's access to transplantation. ...
1,748 results